The estimated Net Worth of International Inc & Subsidi... is at least $4.92 million dollars as of 27 February 2004. International Subsidi owns over 16,000 units of Cerus stock worth over $4,495,035 and over the last 21 years International sold CERS stock worth over $423,675.
International has made over 5 trades of the Cerus stock since 2004, according to the Form 4 filled with the SEC. Most recently International sold 16,000 units of CERS stock worth $62,080 on 27 February 2004.
The largest trade International's ever made was selling 37,000 units of Cerus stock on 20 February 2004 worth over $144,670. On average, International trades about 21,460 units every 3 days since 2004. As of 27 February 2004 International still owns at least 2,192,700 units of Cerus stock.
You can see the complete history of International Subsidi stock trades at the bottom of the page.
International's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash et Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: